ChemicalBook
Chinese Japanese Germany Korea

Solifenacin succinate

Description Proper Usage Precautions Possible Side effects
Solifenacin succinate
Solifenacin succinate structure
CAS No.
242478-38-2
Chemical Name:
Solifenacin succinate
Synonyms
Vesikur;YM 67905;vesicare;Solfenacin;IsoprenalinoeSulfate;solifenacin succinate;Solefinacin Succinate;Solifenacin Succinate 1;Solifenacin Succinate API;Solifenacin succinate, >=98%
CBNumber:
CB3500859
Molecular Formula:
C11H19NO7S
Formula Weight:
480.56
MOL File:
242478-38-2.mol

Solifenacin succinate Properties

Melting point:
~145°
Merck 
14,8712
CAS DataBase Reference
242478-38-2(CAS DataBase Reference)
FDA UNII
KKA5DLD701
SAFETY
  • Risk and Safety Statements
RTECS  NW7136000
HS Code  29339900

Solifenacin succinate price More Price(6)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
TCI Chemical S0944 Solifenacin Succinate >98.0%(HPLC) 242478-38-2 25mg $75 2020-06-24 Buy
TCI Chemical S0944 Solifenacin Succinate >98.0%(HPLC) 242478-38-2 100mg $224 2020-06-24 Buy
Cayman Chemical 17320 Solifenacin (succinate) ≥98% 242478-38-2 10mg $25 2020-06-24 Buy
Cayman Chemical 17320 Solifenacin (succinate) ≥98% 242478-38-2 25mg $38 2020-06-24 Buy
Cayman Chemical 17320 Solifenacin (succinate) ≥98% 242478-38-2 50mg $69 2020-06-24 Buy

Solifenacin succinate Chemical Properties,Uses,Production

Description

Solifenacin succinate is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence.

Proper Usage

  1. This medication should be taken with liquids and swallowed whole. It may be taken with or without food.
  2. Take only the amount of this medication that has been prescribed for you by your doctor; taking more than the prescribed amount can cause adverse effects.
  3. If you miss a dose of this medication, begin taking it again the next day. Do not take two doses of solifenacin succinate in the same day.

Precautions

  1. Individuals with any of the following medical problems should not take this medication: urinary retention, gastric retention, narrow angle or uncontrolled glaucoma, or severe kidney problems. Solifenacin succinate can aggravate each of these conditions.
  2. Solifenacin succinate may cause blurred vision; do not engage in potentially dangerous activities such as driving until you know the effect of the medication on your vision.
  3. This medication, like all anticholinergic medications, may cause drying of the mouth. Since continued dryness of the mouth can increase the risk of dental disease, alert your dentist if you are taking this medication.
  4. Like all anticholinergic medications, solifenacin succinate can cause or worsen constipation.
  5. Because of decreased sweating, this medication can cause heat prostration when used in a very hot environment.
  6. This medication has not been studied in pregnant women. However, it has been shown in animal studies to impact preand postnatal development. If you are pregnant, or planning to become pregnant, do not start this medication before you have discussed it with your physician.
  7. It is not known whether solifenacin succinate passes into breast milk. Women who taking this medication and wish to breastfeed should discuss it with their physician.

Possible Side effects

  1. Side effects that are expected with this type of medication and do not require medical attention unless they continue or are bothersome: dry mouth; dry eyes; constipation, blurred vision, difficult urination.
  2. Less common side effect that should be reported to your physician: severe abdominal pain.
  3. Symptoms of overdose: severe central anticholinergic effects, including blurred vision; clumsiness or unsteadiness; confusion; seizures; severe diarrhea; excessive watering of the mouth; increasing 240 Multiple Sclerosis: A Self-Care Guide to Wellness muscle weakness (especially in the arms, neck, shoulders, and tongue); muscle cramps or twitching; severe nausea or vomiting; shortness of breath; slow heartbeat; slurred speech; unusual irritability, nervousness, or restlessness; unusual tiredness or weakness.

Description

Solifenacin is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. M3 receptors have been implicated in neurally evoked smooth muscle contractions of the bladder, and M2 receptors have also been suspected of playing a role because of their dominance in the detrusor muscle. Solifenacin displays affinity for both M3 and M2 receptors with Ki values of 9.9nM and 120 nM, respectively. Since muscarinic salivary glands are of the M3 persuasion, a common side effect of antimuscarinic therapy is dry mouth. At the cellular level, solifenacin possesses a selective preference for bladder over salivary gland that is 15-fold greater than that of atropine suggesting a lower probability of inducing dry mouth at pharmacologically relevant doses. The synthesis of solifenacin involves the preparation of racemic 1-phenyl- 1,2,3,4-tetrahydroisoquinoline via cyclization of N-(2-phenylethyl)benzamide, and subsequent reaction with ethyl chloroformate and transesterification with (R)- 3-quinuclidinol. Chiral chromatography affords the isolation of the desired diastereomer. Alternatively, 1-phenyl-1,2,3,4-tetrahydroisoquinoline may be subjected to optical resolution with (+)-tartaric acid prior to treatment with ethyl chloroformate and subsequent transesterification. The pooled results of four phase III trials concluded that 63% of women receiving 5mg of solifenacin once daily and 68% of women receiving 10mg once daily reported a 50% or more reduction in urgency episodes, compared to 44% of women taking placebo. This compares with a 53% reduction in patients receiving tolterodine twice daily. In another placebo-controlled trial, with the change in the number of micturitions in a 24-h period as the primary endpoint, once-daily solifenacin recorded an 18% decrease for a 5-mg dose and a 21% decrease for a 10-mg dose compared to 10% with placebo. Pharmacokinetic studies have demonstrated that solifenacin has an oral bioavailability of 90%, a long elimination half-life (50 h), low clearance (9.39 L/h), a mean Vss of 599 L, a Cmax of approximately 14 ng/mL, and a time to maximal plasma concentration of 4 h making it suitable for q.d. dosing. Furthermore, these PK parameters are not affected by food ingestion. Solifenacin is excreted predominantly in the feces with only 3–6% found in urine. It is contraindicated in patients with hepatic impairment, gastric retention, urinary retention, or uncontrolled narrow angle glaucoma. Further precautions, such as dose adjustment, should be considered for patients with concurrent use of ketoconazole or other potent CYP3A4 inhibitors or for patients with a history of QT prolongation or currently on medications known to prolong the QT interval. Finally, while other muscarinic antagonists have been explored in the treatment of irritable bowel syndrome (IBS), it is too early to predict the therapeutic utility of solifenacin for IBS although animal studies are promising.

Chemical Properties

White Solid

Originator

Yamanouchi (Japan)

Uses

Muscarinic M3 receptor antagoinst. Used in treatment of urinary incontinence.

Uses

sedative

Uses

Solifenacin succinate is a urinary antispasmodic of the antimuscarinic class.

brand name

Vesicare (Astellas).

General Description

Solifenacin succinate (Vesicare),(+)-(1S, 3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate, is a competative antagonistfor M1, M2, and M3 receptor subtypes. One of the issues surroundingthe use of such antagonists is the selectivity for thebladder over other tissue such as the salivary glands. It isreported that the selectivity of solifenacin for bladder muscarinicreceptors over salivary receptors is superior to theeffects observed with oxybutynin.

Solifenacin succinate Preparation Products And Raw materials

Raw materials

Preparation Products


Solifenacin succinate Suppliers

Global( 238)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86-571-85586718
+86-571-85864795 sales@capotchem.com China 19929 60
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21821 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 1817 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 22626 55
Shanghai Time Chemicals CO., Ltd.
+86-021-57951555
+86-021-57951555 jack.li@time-chemicals.com CHINA 1365 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 E-mail:sales03@shyrchem.com
+86-21-34979012 sales03@shyrchem.com CHINA 739 60
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 24723 60
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 30045 58
Shenzhen Nexconn Pharmatechs Ltd
15013857715
admin@nexconn.com CHINA 3035 58
Jinan Carbotang Biotech Co.,Ltd.
+86 15866703830
figo.gao@foxmail.com CHINA 1017 58

View Lastest Price from Solifenacin succinate manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2019-12-26 Solifenacin succinate
242478-38-2
US $0.00-0.00 / KG 1mg 99% HPLC 2000tons Shaanxi Dideu Medichem Co. Ltd
2018-07-26 Solifenacin succinate
242478-38-2
US $15.00 / KG 1KG 98% 150KG career henan chemical co
2018-07-26 Solifenacin succinate
242478-38-2
US $15.00 / KG 1KG 98% 150KG career henan chemical co

242478-38-2(Solifenacin succinate)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved